Accelerated wound closure · BPC-157 vs control
Plate 06.01
Sikiric et al. 2015 · Alkali-burn rat model · DOI 10.2174/138161210793292546
Read note →
Facility live · CET
Access Catalogue →
The molecular infrastructure European research deserves.
Analytically verified research compounds. Shipped from Zürich under chain-of-custody. Every vial traceable to its chromatogram.
Purity99.41%
Retention4.62 min
MethodRP-HPLC
MobileACN/0.1% TFA
Flow1.0 mL/min
UV220 nm
● Live feed · SM-ZRH
QC-04 · cam 01
Feed · Analytical bay 3
Frame · 0428
Batches in queue7
Released · 24h12
Mean purity99.41%
EU shipments live38
Cold-chain incidents0
Uptime99.98%
01 · Compound Catalogue
Twelve compounds in circulation. Every vial traceable.
ReleaseQ4 / 2026
SKU count12
Mean purity99.27%
HPLC verified100%
02 · Reference Primer
On peptides, peptide character, and small molecules.
A short primer for investigators newly approaching peptide research. The chemistry, the classification, and the reasons these compounds behave differently to the small molecules most of pharmacology was built on.
Figure 01 · Peptide classification
Source · reference material
Primer · SM-REF-01 · v01.2026
Peptides sit between two worlds.
A peptide is a chain of amino acids held together by peptide bonds. Below roughly fifty residues we speak of peptides; beyond that threshold the chain takes on the folding, regulatory, and functional properties of a protein. In the other direction, below around ten residues, the classification begins to blur into the territory of small molecules, because their size, specificity, and mode of action start to converge.
Character defines behaviour.
Peptide character determines how a compound distributes, how long it survives in circulation, whether it crosses membranes unassisted, and which receptors it engages. A tripeptide like GHK-Cu behaves nothing like a long-chain analogue such as Retatrutide, and neither behaves like a classical orally-bioavailable small molecule. Classification is not taxonomy for its own sake. It is the starting point for any competent protocol.
Class I
Short peptides
2 – 10 residues. High receptor specificity, short half-life, rapid proteolysis.
Class II
Mid-chain peptides
10 – 50 residues. Discrete tertiary character. Most therapeutic-grade analogues sit here.
Class III
Protein-scale
50+ residues. Folded structure, full enzymatic and regulatory behaviour.
03 · Analytical Verification
Batch SM-2025-Q4-0418 · Chromatogram inspection.
Chromatogram · Batch SM-2025-Q4-0418 · SM-2025-Q4-0418
UV 220 nm · 1.0 mL/min
ColumnC18 · 4.6×150mm · 5µm
Mobile phaseACN / 0.1% TFA
Injection10 µL · 1.0 mg/mL
Temperature25.0 °C
Batch Release Statement. Batch SM-2025-Q4-0418 has been analytically reviewed against internal release specification SOP-QC-014 / Rev 06. RP-HPLC chromatographic analysis returned an integrated peak purity of 99.41% at 220 nm with no impurity exceeding 0.30%. Endotoxin assay (LAL) returned < 0.05 EU/mg. The batch is released for European research distribution under chain-of-custody protocol CC-EU-2026. Release is contingent on cold-chain integrity at 2–8°C through final hand-off.
Download COA · SM-2025-Q4-0418.pdf →
Download COA · SM-2025-Q4-0418.pdf →
Dr. Daniel Brunner
Quality Director · SM-ZRH
04 · Biological Context
Why peptides behave the way they do in the body.
Figure 02 · Peptide digestion pathway
Protein → peptides → amino acids
Schematic · qualitative reference
SM-REF-02 · v01.2026
01 · Hydrolysis
Proteins become peptides.
Dietary proteins enter the gastrointestinal tract as long amino-acid chains. Pepsin in the stomach initiates hydrolysis; trypsin and chymotrypsin in the small intestine continue the process. The chains fragment into shorter peptides of varying length. This is why oral bioavailability is the hard problem of peptide therapeutics.
02 · Absorption
Shorter chains survive longer.
Di- and tri-peptides are absorbed through the intestinal epithelium via specific transporters, primarily PEPT1. Longer peptides are typically degraded before absorption. This selective survival explains why many peptide therapeutics are delivered parenterally, and why short-chain compounds occupy a distinct pharmacological space.
03 · Reduction
Amino acids as the terminal state.
Inside the enterocyte, intracellular peptidases complete hydrolysis into free amino acids. These are exported to the portal circulation. From a research standpoint this means that investigating intact peptide activity requires careful attention to route, formulation, and enzymatic environment, not only receptor affinity.
05 · Molecular Intelligence
Scroll horizontally · 04 plates
Four molecules under live inspection.
06 · Evidence Wall
Reconstructed datasets from peer-reviewed literature.
Mercury series denotes Swiss Molecules data. Carbon series denotes comparator.
Sustained GH & IGF-1 response · CJC-1295
Plate 06.02
Teichman et al. 2006 · Healthy adult males · DOI 10.1210/jc.2005-0735
Read note →
Body-weight reduction · Retatrutide 12 mg vs placebo
Plate 06.03
Jastreboff et al. 2023 · TRIUMPH Phase 2 · DOI 10.1056/NEJMoa2301972
Read note →
Batch purity · vendor benchmark (HPLC)
Plate 06.04
Internal benchmark · 12 vendors · 240 batches · 2024–2026
Read note →
“Chain-of-custody chromatography is not a feature. It is the precondition for calling something research-grade at all.” — Operating credo · Swiss Molecules · Zürich
07 · Protocol Intelligence
Operational notes for qualified investigators.
Reconstitution
Reconstitute lyophilized peptides in bacteriostatic water for injection (BWFI, 0.9% benzyl alcohol) at 2 mg/mL unless an alternative diluent is specified by your study protocol. Inject diluent against the inner wall of the vial. Do not agitate. Permit 30 seconds for hydration prior to gentle inversion.
Download SOP-REC-02 PDF →Storage & chain
Lyophilized vials are stable at -20°C for 24 months from date of manufacture. Reconstituted material is stable at 2–8°C for 28 days under aseptic handling. Avoid repeated freeze-thaw cycles. All shipments transit under continuous cold-chain monitoring; investigators should verify integrity tag prior to acceptance.
Download SOP-STO-01 PDF →Handling & documentation
All handling should occur within a class-II laminar flow cabinet under standard aseptic technique. Each vial carries a QR-traceable batch identifier linked to the originating chromatogram, COA, and release statement. We recommend laboratory record-keeping that captures lot, reconstitution date, and concentration to maintain study reproducibility.
Download SOP-HND-04 PDF →
08 · Logistics & Chain-of-Custody
Origin · Zürich. Distribution · European research network.
● Live · 38 shipments in transit
SM-ZRH · 47.3769°N / 8.5417°E
Operational standards
Origin facilitySM-ZRH · CH
Cold-chain integrity2–8 °C · verified
Carrier protocolDHL Express · Med
InsuranceFull-value · CH-EU
TrackingEnd-to-end · SHA-signed
CustomsEU compliant · pre-cleared
PackagingDiscreet · neutral exterior
Mean transit36 h · DACH
Regulatory Notice · Research Use Only
All compounds offered by Swiss Molecules are sold strictly for in-vitro laboratory and pre-clinical research applications. The materials are not intended for human consumption, therapeutic use, diagnostic procedures, cosmetic application, or veterinary use. Customers acknowledge that they are qualified scientific investigators operating in a recognised research setting and assume full responsibility for compliance with applicable national and EU regulations governing the handling, storage, and final disposition of research compounds.
